HTHaruhiko Takeda

Haruhiko Takeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haruhiko Takeda has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroshi Seno

    Department of Gastroenterology and Hepatology Graduate School of Medicine Kyoto University Kyoto Japan

    45 shared publications
  • Yuji Eso

    Department of Gastroenterology and Hepatology, Graduate School of Medicine Kyoto University Kyoto Japan

    45 shared publications
  • Atsushi Takai

    Department of Gastroenterology and Hepatology, Graduate School of Medicine Kyoto University Kyoto Japan

    43 shared publications
  • Eriko Iguchi

    Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University , 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507

    43 shared publications
  • Hiroyuki Marusawa

    Department of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan

    43 shared publications
  • Ken Kumagai

    Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University , 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507

    42 shared publications

Latest Publications

  • MSH2 prevents liver tumorigenesis by regulating cell cycle checkpoints under chronic inflammation

    by Shigeharu Nakano, Atsushi Takai, Eriko Iguchi, Yosuke Fujii, Haruka Amino, Masayuki Ueno, Takahiko Ito, Mari Teramura, Masako Mishima, Ken Kumagai, et al.

    The DNA mismatch repair (MMR) system plays a critical role in maintaining genomic integrity and preventing tumorigenesis. Although MutS homolog 2 (MSH2) is a key component of the MMR system and is dysregulated in human hepatocellular carcinoma (HCC), the molecular mechanism of MSH2 in the process of HCC development under chronic inflammatory conditions remains unclear. To investigate the function of MSH2 in inflammation-associated hepatocarcinogenesis, we treated hepatocyte-specific Msh2-knockout (Msh2 KO) mice with 0.02% thioacetamide for 30 weeks to induce chronic liver inflammation and examined their phenotype. Msh2 KO mice exhibited higher liver tumor incidence than wild-type mice, with no major differences in inflammation or fibrosis. Whole-exome sequencing analysis revealed that genetic alterations with defective MMR-associated signatures were increased in Msh2 KO tumors, though no common cancer driver genes were identified. Transcriptome analysis revealed enrichment of cell cycle-related gene sets, including the G2M checkpoint and E2F targets. Functional assays further demonstrated that MSH2 downregulation impaired ATM–CHK2-mediated DNA damage response and promoted cell cycle acceleration. MSH2 exerts its tumor-suppressive effects in hepatocytes not only through canonical MMR but also by regulating the cell cycle via the ATM–CHK2 axis.

  • Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study

    by Masayuki Ueno, Haruhiko Takeda, Atsushi Takai, Makoto Umeda, Hiroki Morimura, Shunsuke Okuyama, Norihiro Nishijima, Satoru Iwamoto, Shigeharu Nakano, Shu Nagatomo, et al.

    Aim: Atezolizumab plus bevacizumab (Atezo+Bev) therapy is the preferred first‐line treatment for advanced hepatocellular carcinoma (HCC). However, the efficacy of Atezo+Bev is limited in patients with a CRAFITY score of 2 (C‐reactive protein ≥ 1 mg/dL and alpha‐fetoprotein [AFP] ≥ 100 ng/mL). This study compared the efficacy and safety of lenvatinib and Atezo+Bev in these patients. Methods: We retrospectively analyzed 774 patients treated with lenvatinib or Atezo+Bev as first‐line treatment for advanced HCC between October 2020 and December 2023 across 11 hospitals in Japan. Among them, 90 patients (11.6%) had a CRAFITY score of 2. Progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profiles were compared. Results: Baseline characteristics were similar, except tumor size and AFP levels, which were higher in the Atezo+Bev group. Median PFS was significantly longer in the lenvatinib group compared to the Atezo+Bev group (6.0 vs. 2.3 months; hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.32–0.95]; p = 0.032). The median OS was not significantly different between the two groups (9.8 vs. 5.2 months; HR: 0.66, 95% CI: 0.41–1.08; p = 0.101). The DCR (62.0% vs. 30.0%; p = 0.003) and the occurrence of grade ≥ 3 treatment‐related adverse events (46.0% vs. 20.0%; p = 0.014) were significantly higher in the lenvatinib group than in the Atezo+Bev group. Conclusion: Lenvatinib provided a significantly longer PFS than Atezo+Bev in patients with HCC and a baseline CRAFITY score of 2, whereas OS did not significantly differ between the two groups. These findings may serve as a cornerstone for developing biomarker‐based strategies in first‐line treatment selection for this patient population.


  • Open Access

    TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential

    by Masako Mishima, Atsushi Takai, Haruhiko Takeda, Eriko Iguchi, Shigeharu Nakano, Yosuke Fujii, Masayuki Ueno, Takahiko Ito, Mari Teramura, Yuji Eso, et al.

    Telomerase reverse transcriptase (TERT) gene aberration is detectable in >80% of cases with hepatocellular carcinoma (HCC). TERT reactivation is essential for cellular immortalization because it stabilizes telomere length, although the role of TERT in hepatocarcinogenesis remains unelucidated. To elucidate the significance of aberrant TERT expression in hepatocytes in inflammation‐associated hepatocarcinogenesis, we generated Alb‐Cre;TertTg mice, which overexpress TERT in the liver and examined their phenotype during chronic inflammation. Based on transcriptome data from the liver tissue of Alb‐Cre;TertTg mice, we examined the role of TERT in hepatocarcinogenesis in vitro. We also evaluated the relationship between TERT and cell‐cycle‐related molecules, including p21, in HCC samples. The liver tumor development rate was increased by TERT overexpression during chronic inflammation, especially in the absence of p53 function. Gene set enrichment analysis of liver tissues revealed that gene sets related to TNF‐NFκB signaling, cell cycle, and apoptosis were upregulated in Alb‐Cre;TertTg liver. A luciferase reporter assay and immunoprecipitation revealed that TERT interacted with NFκB p65 and enhanced NFκB promoter activity. On the other hand, TERT formed protein complexes with p21, cyclin A2, and cyclin E and promoted ubiquitin‐mediated degradation of p21, specifically in the G1 phase. In the clinical HCC samples, TERT was highly expressed but p21 was conversely downregulated, and TERT expression was associated with the upregulation of molecules related to the cell cycle. Taken together, the aberrant upregulation of TERT increased NFκB promoter activity and promoted cell cycle progression via p21 ubiquitination, leading to hepatocarcinogenesis. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch‐repair deficiency

    by Kenta Makino, Takamichi Ishii, Haruhiko Takeda, Yoichi Saito, Yukio Fujiwara, Masakazu Fujimoto, Takashi Ito, Satoshi Wakama, Ken Kumagai, Fumiaki Munekage, et al.

    Cholangiolocarcinoma (CLC) is a primary liver carcinoma that resembles the canals of Hering and that has been reported to be associated with stem cell features. Due to its rarity, the nature of CLC remains unclear, and its pathological classification remains controversial. To clarify the positioning of CLC in primary liver cancers and identify characteristics that could distinguish CLC from other liver cancers, we performed integrated analyses using whole‐exome sequencing (WES), immunohistochemistry, and a retrospective review of clinical information on eight CLC cases and two cases of recurrent CLC. WES demonstrated that CLC includes IDH1 and BAP1 mutations, which are characteristic of intrahepatic cholangiocarcinoma (iCCA). A mutational signature analysis showed a pattern similar to that of iCCA, which was different from that of hepatocellular carcinoma (HCC). CLC cells, including CK7, CK19, and EpCAM, were positive for cholangiocytic differentiation markers. However, the hepatocytic differentiation marker AFP and stem cell marker SALL4 were completely negative. The immunostaining patterns of CLC with CD56 and epithelial membrane antigen were similar to those of the noncancerous bile ductules. In contrast, mutational signature cluster analyses revealed that CLC formed a cluster associated with mismatch‐repair deficiency (dMMR), which was separate from iCCA. Therefore, to evaluate MMR status, we performed immunostaining of four MMR proteins (PMS2, MSH6, MLH1, and MSH2) and detected dMMR in almost all CLCs. In conclusion, CLC had highly similar characteristics to iCCA but not to HCC. CLC can be categorized as a subtype of iCCA. In contrast, CLC has characteristics of dMMR tumors that are not found in iCCA, suggesting that it should be treated distinctly from iCCA. © 2024 The Pathological Society of Great Britain and Ireland.


  • Open Access

    ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway

    by Takeharu Nakamura, Yoshihiro Nishikawa, Masahiro Shiokawa, Haruhiko Takeda, Masataka Yokode, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Hiroyuki Yoshida, Hirokazu Okada, et al.

    The prognosis of gallbladder cancer (GBC) remains poor, and a better understanding of GBC molecular mechanisms is important. Genome sequencing of human GBC has demonstrated that loss‐of‐function mutations of E74‐like ETS transcription factor 3 (ELF3) are frequently observed, with ELF3 considered to be a tumour suppressor in GBC. To clarify the underlying molecular mechanisms by which ELF3 suppresses GBC development, we performed in vivo analysis using a combination of autochthonous and allograft mouse models. We first evaluated the clinical significance of ELF3 expression in human GBC tissues and found that low ELF3 expression was associated with advanced clinical stage and deep tumour invasion. For in vivo analysis, we generated Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3f/f (KPCE) mice and Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3wt/wt (KPC) mice as a control and analysed their gallbladders histologically. KPCE mice developed larger papillary lesions in the gallbladder than those developed by KPC mice. Organoids established from the gallbladders of KPCE and KPC mice were analysed in vitro. RNA sequencing showed upregulated expression of epiregulin (Ereg) in KPCE organoids, and western blotting revealed that EGFR/mechanical targets of rapamycin complex 1 (mTORC1) were upregulated in KPCE organoids. In addition, ChIP assays on Elf3‐overexpressing KPCE organoids showed that ELF3 directly regulated Ereg. Ereg deletion in KPCE organoids (using CRISPR/Cas9) induced EGFR/mTORC1 downregulation, indicating that ELF3 controlled EGFR/mTORC1 activity through regulation of Ereg expression. We also generated allograft mouse models using KPCE and KPC organoids and found that KPCE organoid allograft tumours exhibited poorly differentiated structures with mTORC1 upregulation and mesenchymal phenotype, which were suppressed by Ereg deletion. Furthermore, EGFR/mTORC1 inhibition suppressed cell proliferation and epithelial–mesenchymal transition in KPCE organoids. Our results suggest that ELF3 suppresses GBC development via downregulation of EREG/EGFR/mTORC1 signalling. EGFR/mTORC1 inhibition is a potential therapeutic option for GBC with ELF3 mutation. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

    by Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, et al.

    Intestinal metaplasia (IM) is a risk factor for gastric cancer following infection with Helicobacter pylori. To explore the susceptibility of pure gastric IM to cancer development, we investigated genetic alterations in single IM gastric glands. We isolated 50 single IM or non-IM glands from the inflamed gastric mucosa of 11 patients with intramucosal gastric carcinoma (IGC) and 4 patients without IGC; 19 single glands in the noninflamed gastric mucosa of 11 individuals from our cohort and previous dataset were also included as controls. Whole-exome sequencing of single glands revealed significantly higher accumulation of somatic mutations in various genes within IM glands compared with non-IM glands. Clonal ordering analysis showed that IM glands expanded to form clusters with shared mutations. In addition, targeted-capture deep sequencing and copy number (CN) analyses were performed in 96 clustered IM or non-IM gastric glands from 26 patients with IGC. CN analyses were also performed on 41 IGC samples and The Cancer Genome Atlas-Stomach Adenocarcinoma datasets. These analyses revealed that polyclonally expanded IM commonly acquired CN aberrations (CNA), including amplification of chromosomes 8, 20, and 2. A large portion of clustered IM glands typically consisted of common CNAs rather than other cancer-related mutations. Moreover, the CNA patterns of clustered IM glands were similar to those of IGC, indicative of precancerous conditions. Taken together, these findings suggest that, in the gastric mucosa inflamed with H. pylori infection, IM glands expand via acquisition of CNAs comparable with those of IGC, contributing to field cancerization.Significance:This study contributes to our understanding of gastric intestinal metaplasia as a risk factor for gastric adenocarcinoma via their multifocal expansion and acquisition of CNAs and somatic mutations.

  • Open Access

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

    by Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, et al.

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

  • Open Access

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

    by Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, et al.

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

  • Open Access

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

    by Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, et al.

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

  • Open Access

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization

    by Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, et al.

    Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization